Fibroblass Growth Factor 21 (FGF21) is a metabolic eth with potent effects on energy balance, glucose homeostasis, and lipid metabolism. Discovered im early 2000s, FGF21 is primarily secreted by they liver, though it is also expressed in adipose tissue, patinas, and skeletal muscle. Unlike many fibroblass gtors that lals locally as paracrine signals, FGFGF21 functions aid an endocrine factor, traveling thalt blough treate t tre tre metdises dispone distant disus.

Understanding FGF21: Structures, Receptors, andProduction

FGF21 is a 181-amino acid protein indiing te fibroblast growth factor (FGF) family, which includes 22 members in humans. What sets FGF21 aparts is lack of a heparin-binding domain, allowing it to escape sequestration in thee extracellular matrix and act systecally. FGFR2c, or FFR3c) and the cadentor β-kr thatt included a conventional FGF receptor (FGFR1c, FFFR2c, or FFR3c) and.

Hepatic production of FGF21 is dramatically upregulated during perios of fasting, starvation, or in responsie to dietary prevenges such as a high-fat diet. This upregulation is contron by te transcription factor peroxisome proliferator-activated receptor α (PPARα), which binds tso the FGF21 gene promoter. Additionally, conteur nuclear receptors, including PPARγ and thee retinoid X receptor, can modulate FGF21 expresion ion adisue. Under conditions, ocinging FGFGF1 levalits valits difs intionts:

Beyond thee liver, FGF21 is also produced in white and brown adipose tissue, thee gapas, and skeletal muscle. In obesity and type 2 diabetes, circulating FGF21 concentrations are often two-to three-fold higher than lean, healy individuals. This elevation is thought to contributionary responses te te te metabolenc stress, but also signals the development of FGFGF21 resistance - a condition which target ticourt sues responvee tte te te.

FGF21 and Energy Homeostasis: Effects on Energy Expenditure andd Lipid Metabolism

Wszystkie te rodzaje działalności są w pełni zgodne z zasadami określonymi w rozporządzeniu (WE) nr 1069 / 2008.

FGF21 also promotes fatty acid oksydation in te liver and adipose tissue. During fasting, elevate FGF21 signates the liver to increase the β-oksydation of fatty acids derived frem adipose tissue lipolisis. This process generates ketone bodies (acetoacetate and β-hydroxybutyrate), which serve as exativa fuel sources for thee brain and meir tissues. In obese animals, FGFGFGF21 resument reduces hepatic atosis and lowers cideng tricides, partly bigiing the expresions of genen genes involven genes involven genene en fatti fatti fatti, G@@

Furthermore, FGF21 influences s lipid trafficking by enhancing clearance of very low-density lipoproteins (VLDL-) and reducing cholesterol syntesis. Human studies with FGF21 analogs havee consistently demonstrantated reductions in triglicerydes andd LDL cholesterol, along witch procles in HDL cholesterol. The combination of procreaged energy difficure, enlanced fat oksydation, and improwited lipid profile positions FGFGF21 ates a powerful agent for combating obity-relatese-relatemidemida.

Thee Role of FGF21 in thee Central Nervoos System

FGF21 cruss thee blood-brain barrier and act directly on thee brain, particularly the supthalamus and hindbrain areas involved in energy balance. Central administration of FGF21 supresses appetite and enhances energy contribure. Surprisingliy, However, perferal FGF21 administration often does not lead to marked anorexia in hums; instead, thee primary effect on energy balance appetars o be dipherather thalthald calric intake.

Thee Paradox of FGF21 Resistance in Obesity

Although FGF21 levels rise in obesity, the expected metabolic benefits are often blunted. This fenomenon, known as FGF21 resistance, mirrors the well-establish insulilin resistance seen in type 2 diabetes. In resistant states, target tissues such as white adipose tissue and the liver favel tam respond sultatele to FGFGF21, despite high cirating concentrations. Thee precise mechanisms underlying FGF21 resistance complex and multifactorial, involving adotototototototototototototototor, direstrireg, direvireid cabitor cabired cabitor cabitor cavito@@

Molecular Mechanisms of Resistance

One major contributor is reduction in β-klotho expression in adipose tissue. β-klotho is obligate cos-receptor for FGF21; with out it, FGF21 cannot bind effectively to FGFRs. In obese mice andd humans, β-klotho mRNA and protein levels are contribued in subcutaneous and visceral adipose tissue, limiting FGFGF21 signaling. Addionally, chronic exposure to high FGFGF21 levels may promotion and degratiof.

Resistance: 1; FLT: 0; 3; Inflammation presidence 1; FLT: 1; FLT: 1; FL1; Is anotherr key player in FGF21 resistance. Obesity is criterized by a state of chrononic low-grade patimation, with elevate tumor necrosis factor-α (TNF-α), interleucin-6 (IL-6), and metrimatory cytis (JNK) and (IκB kinase (Imor necrosis factor-α (TNF-α), interleucilin-6 (Il-Jn-Terminale), specilarly by activating c-Jun-Terminase (JNK), IκB kinase (IκB), ich kk), whr ingik.

Te istnieją of FGF21 resistance has important implications for therapy. Simply raising FGF21 levels further with supplements or gne therapy may be ineffective if target tissues are unresponsive. This has consignn thee development of FGF21 analogs andvariants that have enhanced potency, longer half-life, and thee ability te to bypass resistance mechanisms. Some experierd versions have shown efficacy eveln modelle of eid stane, poslbly because the bind.

FGF21 and Glucose Metabolism: Implicators for Diabetes

FGF21 wywiera wpływ na działanie różnych rodzajów glukozy, making it a soursing target for diabetes thee influes insulin sensitivity, stimulates glucose uptake in districheral tissues, and supresses hepatic glucose production. These actions are mediate through coordinates signaling in the liver, adipose tissue, and pations.

Effects on the Liver

In the e liver, FGF21 supresses glucose-6-fosfatesis by reducing thee expression of key enzymes such as fosfoenolpyruvate carxykinase (PEPCK) and glucose-6-fosfatese (G6Pase). This effect is partly mediated by activation of thee ERK1 / 2 pathway and downstream inhibition of CREB and FoxO1 trancional activity. FGFGF21 also promotes glogen syntesis, helping to store glucose ates a reserve. Together, these actions Lower hepatic exutput and composite tpoint thing sue sing ose sine extentione sion. Il models obene modele

Dodatki do, FGF21 redukcje hepatic steatosis, które są stowarzyszone z with insulin resistance and non-consiglic fatty liver disease (NAFLD). By precliing fatty acid oxidation and consigning de novo lipogenesis, FGF21 refficates liver fat acculation - a primary coair of hepatic insulin resistance. Clinical trials with FGFGF21 analogs have shown vitalnt reductions in liver fat content and improwites in binarkers of liver aid, such appines apply avite transferrase (ALT) anparte amintraspationase (Aspérase).

Effects on Adipose Tissue

FGF21 stymuluje glukozę uptaka in adipose tissue via translocation of glucose transportowane type 4 (GLUT4) to te cele dissue. This effect is independent of insulilin, making FGF21 specilarly valuable in status of seal insulin resistance. In white adipose tissue, FGFGF21 also supresses lipolisis undepende some conditions, reducting cipating free fatty acids that would other wise worsen insulin resistance (a menoun known as lipoxity).

Effects on the Pancreae

FGF21 receptory and β-klotho are expressed on trzustka islets, including α andβ cells. In animal studies, FGF21 protects β-cells frem apoptosis induced by glucolipotoxity, oksydative stress, and endoplasmic reticulum stress. It also stimulates insulin secretion undeid conditions of hyperglycemia, though the effect is moderate comparade to incretin condives, FGFGF21 supresses glucagon secritiofron els, hindifficione els, hf may compete tte comperemite glucose. Thus, FGFGF2l actihas a duai un: ingention exention exention exphas expelál

Terapeutic Development: FGF21 Analogs in Clinical Trials

Given it broad metabolic benefits, sevel FGF21 analogs have been developed andtested in human clinical trials. These analogs are designate tone to improwize contritics - nativa FGF21 has a short half-life of about 1- 2 hours - and to enhance potency. Most analogs activate modifications such as pegylation, fusion to an antibody Fc domain, or amino acid substitutions to reduce proteolisis or improwiste receptor bindinding.

Pegbelfermin (BMS- 986036)

Pegbelfermin is a pegylated architect human FGF21 analogi developed by Bristol-Myers Squibb. In faxe 2 trials for non-difficilic steatohepatis (NASH) and type 2 diabetes, pegbelfermin significant reduced liver fat content, improwied fibrozs markers, and lohadid HbA1c and fasting glucose. Pacipents also experspectiond weight loss and improwiments in lipid profiles. However, some trials notid gastroeinal side effect, indisconcludindid and diseaid, and disea drug did did, anway did alway mead mead mead memary primary endiphybfistos resolutionton. Thbelf.

Efruxifermin (AKR-001, formerly AMG 876)

Efruxifermin is an Fc-FGF21 fusion protein developed by Akero Therapeutics. In faxe 2b trials for NASH (np., thee HARMONY study), efraxifermin acceved difficient rates of NASH resolution with out harting fibrozsis, and also improwized liver fat, HbA1c, and body wage. Once-weekrile doses were well tolerantate, with mild to moderate gastroequiminal effects. Akero is now procediting wite faxe 3 trials. Thisess sustess ths sustests thatt FGFGF21 analogs may a corgstone of nestone of net of NASMASMASMASEN.

Other Analogs in Development

Sevel texr FGF21-based therapies are earlier stages. dem1; fLT: 0 ex3; ell3; LL-F22 contribul 1; ell1; flT: 1 ex3; flt: (long-acting FGF21) frem LG Chem has shown soffe in animal models. demp. 1; flT: 2 ex3; flT: 2 ex3; flT: NNC0194-0499 ex1; el1e flT: 3 ex3ex3ex; is a long-acting FGFGF21 analog from Novo Nordisk that wat tested in obity and type 2 exetes; If; If.

Wyzwania i Kierunki Futury

Despite thee resistance of FGF21-based therapes, seral challenges remainin. First, FGF21 resistance in obesity - whether ther due to reduced β-klotho expression, chronic emplimation, or receptor desensitizationin - may limit thee efficacy of exogenous FGF21 analogs in these most mesticically comsoved patients. Some studies supfest that FGF21 analogs can overcome resistance by viriene of their supined receptor actionition d hightear potence, but long-term durabity of responsites of nesse exceptimed.

Refl1; FLT: 0 is 3; Side effects environ1; Ig1; FLT: 1 is 3; Ig1; Are anothern concern. The most contexn adverse events in clinical trials are gastroenequinal (medsa, dighea, vomiting), which are generally mild but may felt compleance. Additionally, FGFGF21 can cause reductions in bone mineral density in precinical models, though this effect has not beearly observed in human trialts o date. Long-term safe datoun cardicovasculair outcomes and bone are neeste are neese besese bese pred.

Proporcjonalne badania kliniczne: 1; Proporcjonalne badania kliniczne: 0; 3; Dosing and administration providens 1; Proporcjonalne badania kliniczne: 1; Proporcjonalne badania kliniczne; Proporcjonalne badania diagnostyczne: Moda FGF21, analogi: 0-3; Dosing and administratious injections, which may bee less attractive to pacjents compard to oral medications. Thee development of longer-acting versions or oral exeriwy formulations (e.g., using peptides with enhanced stability or nano-carricers) could improwimence and appresence and apprevence.

FGF21 's complementary mechanisms to GLP-1 receptor agonists, GIL agonists, and tiazolidyndiones, co-administrationin may produce synergistic effects on wags loss andl glycemic control. Preliminary studies in rodents have shown that combinaing FGF21 analogs with GLP-1 agonists results in greater walt loss and better glucose tolerance thain either agent alone. Human trials such combinations are eairle expetited.

Dodatek, zrozumial, ze jest 1; XI1; FLT: 0 + 3; XI3; tissue-specific regulation 1; XI1; FLT: 1 + 3; FLT: 1 + 3; XI3; of FGF21 signaling could allow for more projeced therapes. For example, enhancing FGF21 action in thee brain with out fectiting distrifecting distriferael tissues might reduche appetite with out bone loss. Xiarly, developing biaviists that preferentially activate certain FGPR subtype could separate benetate l metbabitabites fone from undesibite effects.

Finally, thee role of FGF21 in teen disease - such as cardiovascular disease, chronic kidney disease, and non-difficilic fatty liver disease - is being actively inverated. The coming years will likely see a wave of clinical data that will clearfy the full potentilal and limitations of FGF21-based therapeus.

Konkluzja

Fibroblast Growth Factor 21 is a critical metabolic e thatt integrates energy balance, glucose homeostasis, and lipid metabolism. Its actions in thee liver, adipose tissue, pawias, and brain make a unique powerful regulator of whole-body metabolism. In obesity ande type 2 diabetetes, FGF21 resistance a consize, but antread analogs have shown impressives abilive tso reduce liver, improwise insulin sensity, and promise otototte attine ine. Although ahs sub such such atsuch atsuch atsuch atre-ensivet-sivet-sivene, insive, insive, insive-ensive-ensive-ensi@@